{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:51:45Z","timestamp":1794361905157,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002160","name":"Jain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002160","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1103618"],"award-info":[{"award-number":["APP1103618"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1136197"],"award-info":[{"award-number":["APP1136197"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dysferlin is a Ca<jats:sup>2+<\/jats:sup>-activated lipid binding protein implicated in muscle membrane repair. Recessive variants in <jats:italic>DYSF<\/jats:italic> result in dysferlinopathy, a progressive muscular dystrophy. We showed previously that calpain cleavage within a motif encoded by alternatively spliced exon 40a releases a 72\u00a0kDa C-terminal minidysferlin recruited to injured sarcolemma. Herein we use CRISPR\/Cas9 gene editing to knock out murine <jats:italic>Dysf<\/jats:italic> exon 40a, to specifically assess its role in membrane repair and development of dysferlinopathy. We created three <jats:italic>Dysf<\/jats:italic> exon 40a knockout (40aKO) mouse lines that each express different levels of dysferlin protein ranging from\u2009~\u200990%,\u2009~\u200950% and\u2009~\u200910\u201320% levels of wild-type. Histopathological analysis of skeletal muscles from all 12-month-old 40aKO lines showed virtual absence of dystrophic features and normal membrane repair capacity for all three 40aKO lines, as compared with dysferlin-null BLAJ mice. Further, lipidomic and proteomic analyses on 18wk old quadriceps show all three 40aKO lines are spared the profound lipidomic\/proteomic imbalance that characterises dysferlin-deficient BLAJ muscles. Collective results indicate that membrane repair does not depend upon calpain cleavage within exon 40a and that\u2009~\u200910\u201320% of WT dysferlin protein expression is sufficient to maintain the muscle lipidome, proteome and membrane repair capacity to crucially prevent development of dysferlinopathy.<\/jats:p>","DOI":"10.1186\/s40478-022-01473-x","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T09:03:08Z","timestamp":1674032588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Minimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice"],"prefix":"10.1186","volume":"11","author":[{"given":"Joe","family":"Yasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia E.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Bournazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances J.","family":"Evesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatius","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse R.","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunda","family":"Nijagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Weisleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra T.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Lemckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"4","key":"1473_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nmd.2021.01.009","volume":"31","author":"U Moore","year":"2021","unstructured":"Moore U et al (2021) Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease. Neuromuscul Disord 31(4):265\u2013280. https:\/\/doi.org\/10.1016\/j.nmd.2021.01.009","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"1473_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/mus.25367","volume":"54","author":"M Fanin","year":"2016","unstructured":"Fanin M, Angelini C (2016) Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve 54(5):821\u2013835. https:\/\/doi.org\/10.1002\/mus.25367","journal-title":"Muscle Nerve"},{"key":"1473_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","volume":"13","author":"JJA Lee","year":"2018","unstructured":"Lee JJA et al (2018) Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy. Mol Ther Nucleic Acids 13:596\u2013604. https:\/\/doi.org\/10.1016\/j.omtn.2018.10.004","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"1473_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/hum.2017.062","volume":"29","author":"RA Potter","year":"2018","unstructured":"Potter RA et al (2018) Systemic delivery of dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther 29(7):749\u2013762. https:\/\/doi.org\/10.1089\/hum.2017.062","journal-title":"Hum Gene Ther"},{"key":"1473_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113210","author":"ML Vallecillo-Z\u00faniga","year":"2021","unstructured":"Vallecillo-Z\u00faniga ML et al (2021) Therapeutic benefit of galectin-1: beyond membrane repair, a multifaceted approach to LGMD2B. Cells. https:\/\/doi.org\/10.3390\/cells10113210","journal-title":"Cells"},{"issue":"10","key":"1473_CR6","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.ymthe.2017.06.025","volume":"25","author":"LV Gushchina","year":"2017","unstructured":"Gushchina LV et al (2017) Treatment with recombinant human MG53 protein increases membrane integrity in a mouse model of limb girdle muscular dystrophy 2B. Mol Ther 25(10):2360\u20132371. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.025","journal-title":"Mol Ther"},{"issue":"2","key":"1473_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1600-0854.2011.01267.x","volume":"13","author":"A Lek","year":"2012","unstructured":"Lek A et al (2012) Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair. Traffic 13(2):185\u2013194. https:\/\/doi.org\/10.1111\/j.1600-0854.2011.01267.x","journal-title":"Traffic"},{"issue":"3","key":"1473_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/tra.12370","volume":"17","author":"GMI Redpath","year":"2016","unstructured":"Redpath GMI et al (2016) Ferlins show tissue-specific expression and segregate as plasma membrane\/late endosomal or trans-golgi\/recycling ferlins. Traffic 17(3):245\u2013266. https:\/\/doi.org\/10.1111\/tra.12370","journal-title":"Traffic"},{"issue":"11","key":"1473_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013854","volume":"5","author":"A de Morr\u00e9e","year":"2010","unstructured":"de Morr\u00e9e A et al (2010) Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS ONE 5(11):e13854. https:\/\/doi.org\/10.1371\/journal.pone.0013854","journal-title":"PLoS ONE"},{"key":"1473_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.540098","author":"H Zhang","year":"2021","unstructured":"Zhang H et al (2021) Abnormal expression of dysferlin in blood monocytes supports primary dysferlinopathy in patients confirmed by genetic analyses. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.540098","journal-title":"Front Neurol"},{"issue":"6936","key":"1473_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature01573","volume":"423","author":"D Bansal","year":"2003","unstructured":"Bansal D et al (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423(6936):168\u2013172. https:\/\/doi.org\/10.1038\/nature01573","journal-title":"Nature"},{"issue":"7","key":"1473_CR12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/hmg\/ddt557","volume":"23","author":"JR McDade","year":"2014","unstructured":"McDade JR, Michele DE (2014) Membrane damage-induced vesicle-vesicle fusion of dysferlin-containing vesicles in muscle cells requires microtubules and kinesin. Hum Mol Genet 23(7):1677\u20131686. https:\/\/doi.org\/10.1093\/hmg\/ddt557","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1473_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1242\/jcs.198861","volume":"130","author":"J Hofhuis","year":"2017","unstructured":"Hofhuis J et al (2017) Dysferlin mediates membrane tubulation and links T-tubule biogenesis to muscular dystrophy. J Cell Sci 130(5):841\u2013852. https:\/\/doi.org\/10.1242\/jcs.198861","journal-title":"J Cell Sci"},{"issue":"1","key":"1473_CR14","doi-asserted-by":"publisher","first-page":"15865","DOI":"10.1038\/s41598-021-95378-9","volume":"11","author":"DY Barefield","year":"2021","unstructured":"Barefield DY et al (2021) Loss of dysferlin or myoferlin results in differential defects in excitation-contraction coupling in mouse skeletal muscle. Sci Rep 11(1):15865. https:\/\/doi.org\/10.1038\/s41598-021-95378-9","journal-title":"Sci Rep"},{"issue":"8","key":"1473_CR15","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1194\/jlr.M090845","volume":"60","author":"VR Haynes","year":"2019","unstructured":"Haynes VR et al (2019) Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice. J Lipid Res 60(8):1350\u20131364. https:\/\/doi.org\/10.1194\/jlr.M090845","journal-title":"J Lipid Res"},{"issue":"12","key":"1473_CR16","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1194\/jlr.RA119000399","volume":"60","author":"AK Agarwal","year":"2019","unstructured":"Agarwal AK et al (2019) Insights into lipid accumulation in skeletal muscle in dysferlin-deficient mice. J Lipid Res 60(12):2057\u20132073. https:\/\/doi.org\/10.1194\/jlr.RA119000399","journal-title":"J Lipid Res"},{"issue":"6","key":"1473_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ajpath.2014.02.005","volume":"184","author":"MD Grounds","year":"2014","unstructured":"Grounds MD et al (2014) Lipid accumulation in dysferlin-deficient muscles. Am J Pathol 184(6):1668\u20131676. https:\/\/doi.org\/10.1016\/j.ajpath.2014.02.005","journal-title":"Am J Pathol"},{"issue":"2","key":"1473_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/jcp.2004.018978","volume":"58","author":"G Cenacchi","year":"2005","unstructured":"Cenacchi G et al (2005) Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 58(2):190. https:\/\/doi.org\/10.1136\/jcp.2004.018978","journal-title":"J Clin Pathol"},{"issue":"6","key":"1473_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.nmd.2020.04.001","volume":"30","author":"H Barzilai-Tutsch","year":"2020","unstructured":"Barzilai-Tutsch H et al (2020) Early pathological signs in young dysf(-\/-) mice are improved by halofuginone. Neuromuscul Disord 30(6):472\u2013482. https:\/\/doi.org\/10.1016\/j.nmd.2020.04.001","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1473_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1152\/physrev.00037.2014","volume":"95","author":"ST Cooper","year":"2015","unstructured":"Cooper ST, McNeil PL (2015) Membrane repair: mechanisms and pathophysiology. Physiol Rev 95(4):1205\u20131240. https:\/\/doi.org\/10.1152\/physrev.00037.2014","journal-title":"Physiol Rev"},{"issue":"12","key":"1473_CR21","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1523\/jneurosci.3560-12.2013","volume":"33","author":"A Lek","year":"2013","unstructured":"Lek A et al (2013) Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J Neurosci 33(12):5085\u20135094. https:\/\/doi.org\/10.1523\/jneurosci.3560-12.2013","journal-title":"J Neurosci"},{"issue":"19","key":"1473_CR22","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1091\/mbc.E14-04-0947","volume":"25","author":"GM Redpath","year":"2014","unstructured":"Redpath GM et al (2014) Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. Mol Biol Cell 25(19):3037\u20133048. https:\/\/doi.org\/10.1091\/mbc.E14-04-0947","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1473_CR23","doi-asserted-by":"publisher","first-page":"12875","DOI":"10.1038\/ncomms12875","volume":"7","author":"V Middel","year":"2016","unstructured":"Middel V et al (2016) Dysferlin-mediated phosphatidylserine sorting engages macrophages in sarcolemma repair. Nat Commun 7(1):12875. https:\/\/doi.org\/10.1038\/ncomms12875","journal-title":"Nat Commun"},{"issue":"8","key":"1473_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011940","volume":"5","author":"A de Morr\u00e9e","year":"2010","unstructured":"de Morr\u00e9e A et al (2010) Calpain 3 Is a rapid-action, unidirectional proteolytic switch central to muscle remodeling. PLoS ONE 5(8):e11940. https:\/\/doi.org\/10.1371\/journal.pone.0011940","journal-title":"PLoS ONE"},{"issue":"15","key":"1473_CR25","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1111\/j.1742-4658.2006.05350.x","volume":"273","author":"MC Lebart","year":"2006","unstructured":"Lebart MC, Benyamin Y (2006) Calpain involvement in the remodeling of cytoskeletal anchorage complexes. Febs J 273(15):3415\u20133426. https:\/\/doi.org\/10.1111\/j.1742-4658.2006.05350.x","journal-title":"Febs J"},{"issue":"6","key":"1473_CR26","doi-asserted-by":"publisher","first-page":"C1226","DOI":"10.1152\/ajpcell.00408.2019","volume":"318","author":"AK Piper","year":"2020","unstructured":"Piper AK et al (2020) Loss of calpains-1 and -2 prevents repair of plasma membrane scrape injuries, but not small pores, and induces a severe muscular dystrophy. Am J Physiol Cell Physiol 318(6):C1226-c1237. https:\/\/doi.org\/10.1152\/ajpcell.00408.2019","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"1473_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1021\/acs.jpcb.0c07143","volume":"125","author":"TW Golbek","year":"2021","unstructured":"Golbek TW et al (2021) Direct evidence that mutations within dysferlin\u2019s C2A domain inhibit lipid clustering. J Phys Chem B 125(1):148\u2013157. https:\/\/doi.org\/10.1021\/acs.jpcb.0c07143","journal-title":"J Phys Chem B"},{"key":"1473_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fphys.2019.00828","volume":"10","author":"DC Bittel","year":"2019","unstructured":"Bittel DC, Jaiswal JK (2019) Contribution of extracellular vesicles in rebuilding injured muscles. Front Physiol 10:828. https:\/\/doi.org\/10.3389\/fphys.2019.00828","journal-title":"Front Physiol"},{"key":"1473_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141295","author":"DC Bittel","year":"2022","unstructured":"Bittel DC et al (2022) Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI141295","journal-title":"J Clin Invest"},{"key":"1473_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091919","author":"DC Bittel","year":"2020","unstructured":"Bittel DC et al (2020) Annexin A2 mediates dysferlin accumulation and muscle cell membrane repair. Cells. https:\/\/doi.org\/10.3390\/cells9091919","journal-title":"Cells"},{"issue":"23","key":"1473_CR31","doi-asserted-by":"publisher","first-page":"15894","DOI":"10.1074\/jbc.M109.009589","volume":"284","author":"C Cai","year":"2009","unstructured":"Cai C et al (2009) Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 284(23):15894\u201315902. https:\/\/doi.org\/10.1074\/jbc.M109.009589","journal-title":"J Biol Chem"},{"issue":"3","key":"1473_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1096\/fj.06-6628com","volume":"21","author":"Y Huang","year":"2007","unstructured":"Huang Y et al (2007) AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. Faseb J 21(3):732\u2013742. https:\/\/doi.org\/10.1096\/fj.06-6628com","journal-title":"Faseb J"},{"issue":"37","key":"1473_CR33","doi-asserted-by":"publisher","first-page":"28529","DOI":"10.1074\/jbc.M110.111120","volume":"285","author":"FJ Evesson","year":"2010","unstructured":"Evesson FJ et al (2010) Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway. J Biol Chem 285(37):28529\u201328539. https:\/\/doi.org\/10.1074\/jbc.M110.111120","journal-title":"J Biol Chem"},{"key":"1473_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.754555","volume":"9","author":"O Ballouhey","year":"2021","unstructured":"Ballouhey O et al (2021) The dysferlin transcript containing the alternative exon 40a is essential for myocyte functions. Front Cell Dev Biol 9:754555. https:\/\/doi.org\/10.3389\/fcell.2021.754555","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"1473_CR35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1212\/01.wnl.0000204358.89303.81","volume":"66","author":"M Sinnreich","year":"2006","unstructured":"Sinnreich M, Therrien C, Karpati G (2006) Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66(7):1114\u20131116. https:\/\/doi.org\/10.1212\/01.wnl.0000204358.89303.81","journal-title":"Neurology"},{"issue":"9","key":"1473_CR36","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ymthe.2017.05.013","volume":"25","author":"T Llanga","year":"2017","unstructured":"Llanga T et al (2017) Structure-based designed nano-dysferlin significantly improves dysferlinopathy in BLA\/J Mice. Mol Ther 25(9):2150\u20132162. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.013","journal-title":"Mol Ther"},{"issue":"10","key":"1473_CR37","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/hmg\/ddq065","volume":"19","author":"W Lostal","year":"2010","unstructured":"Lostal W et al (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19(10):1897\u20131907. https:\/\/doi.org\/10.1093\/hmg\/ddq065","journal-title":"Hum Mol Genet"},{"key":"1473_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jocn.2019.08.068","volume":"71","author":"YC Choi","year":"2020","unstructured":"Choi YC et al (2020) Proteomic analysis of the skeletal muscles from dysferlinopathy patients. J Clin Neurosci 71:186\u2013190. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.068","journal-title":"J Clin Neurosci"},{"issue":"4","key":"1473_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/NEN.0b013e31821350b0","volume":"70","author":"LB Waddell","year":"2011","unstructured":"Waddell LB et al (2011) Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch. J Neuropathol Exp Neurol 70(4):302\u2013313. https:\/\/doi.org\/10.1097\/NEN.0b013e31821350b0","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"1473_CR40","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/hmg\/ddt515","volume":"23","author":"K Sullivan","year":"2014","unstructured":"Sullivan K et al (2014) NF1 is a critical regulator of muscle development and metabolism. Hum Mol Genet 23(5):1250\u20131259. https:\/\/doi.org\/10.1093\/hmg\/ddt515","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1473_CR41","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1369\/0022155411423274","volume":"59","author":"JA Roche","year":"2011","unstructured":"Roche JA et al (2011) Unmasking potential intracellular roles for dysferlin through improved immunolabeling methods. J Histochem Cytochem 59(11):964\u2013975. https:\/\/doi.org\/10.1369\/0022155411423274","journal-title":"J Histochem Cytochem"},{"issue":"12","key":"1473_CR42","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1093\/nar\/gkz433","volume":"47","author":"R Molania","year":"2019","unstructured":"Molania R et al (2019) A new normalization for Nanostring nCounter gene expression data. Nucleic Acids Res 47(12):6073\u20136083. https:\/\/doi.org\/10.1093\/nar\/gkz433","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1473_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/biostatistics\/kxr034","volume":"13","author":"JA Gagnon-Bartsch","year":"2012","unstructured":"Gagnon-Bartsch JA, Speed TP (2012) Using control genes to correct for unwanted variation in microarray data. Biostatistics 13(3):539\u2013552. https:\/\/doi.org\/10.1093\/biostatistics\/kxr034","journal-title":"Biostatistics"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01473-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-022-01473-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01473-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T09:07:25Z","timestamp":1674032845000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-022-01473-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1473"],"URL":"https:\/\/doi.org\/10.1186\/s40478-022-01473-x","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"17 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were conducted in accordance with the guidelines of the Australian National Health and Medical Research Council Australia and approved by the animal ethics committee at the Children\u2019s Hospital at Westmead and Children\u2019s Medical Research Institute (protocol no. CMRI\/CHW-K344). Dysferlin deficient BLAJ mice (B6.A-<i>Dysf<\/i><sup><i>prmd<\/i><\/sup>\/GeneJ) were obtained from the Animal Resources Centre (ARC), Murdoch, Western Australia. Dysferlin exon 40a knockout (40aKO) mice were created and bred in house in a pathogen-free animal care facility at the Children\u2019s Hospital at Westmead. Wildtype (WT) control C57BL\/6 mice were bred in house or sourced from the ARC. All mice were kept in microisolator cages on a 12-h light\/dark cycle, under standard conditions with free access to drinking water and rat and mouse chow (Specialty Feeds, Glen Forrest, Australia).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Sandra T. Cooper is director and shareholder of Frontier Genomics Pty Ltd (Australia). STC currently receives no consultancy fees or other remuneration for this role. Frontier Genomics has no current financial interests that will benefit from publication of these data. 40aKO mouse lines have been provided to Sarepta Therapeutics under license from the University of Sydney and Sydney Children\u2019s Hospitals Network. The remaining authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}